Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatic testing products and services primarily provided to public health authorities. It also focuses on the design of next-generation cell therapies for autoimmune diseases. It uses its platform to develop and screen libraries of novel NK-specific and T-cell specific chimeric antigen receptor and switch receptor designs, which enable control and performance of immune cell-based therapies.
Símbolo de cotizaciónDNA
Nombre de la empresaGinkgo Bioworks Holdings Inc
Fecha de salida a bolsaApr 19, 2021
Director ejecutivoDr. Jason Kelly
Número de empleados834
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 19
Dirección27 Drydock Avenue
CiudadBOSTON
Bolsa de valoresNYSE Consolidated
PaísUnited States of America
Código postal02210
Teléfono18774425362
Sitio Webhttps://investors.ginkgobioworks.com/
Símbolo de cotizaciónDNA
Fecha de salida a bolsaApr 19, 2021
Director ejecutivoDr. Jason Kelly
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos